Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tosedostat - CTI BioPharma

Drug Profile

Tosedostat - CTI BioPharma

Alternative Names: CHR-2797

Latest Information Update: 09 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Developer Azienda Ospedaliera Ospedali Riuniti Marche Nord; Cardiff University; CTI BioPharma
  • Class Amides; Antineoplastics; Benzene derivatives; Cyclopentanes; Esters; Hydroxamic acids; Small molecules
  • Mechanism of Action Aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 21 Apr 2020 National Cancer Institute terminates phase I/II trial in Acute myeloid leukaemia and Myelodysplastic syndromes (In the elderly) in USA (NCT01636609)
  • 13 Apr 2020 Biomarkers information updated
  • 01 Jan 2020 Cardiff University completes a phase II/III trial in Myelodysplastic syndromes, Acute myeloid leukaemia and Precursor cell lymphoblastic leukaemia lymphoma (Combination therapy, In the elderly) in United Kingdom and Denmark (PO) (EudraCT2011-000749-19)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top